FDA 21 CFR Part 812 Investigational Device Exemptions
Navigate FDA 21 CFR Part 812 requirements with expert support for IDE strategy, documentation, risk alignment, and submission readiness. Elexes helps medical device companies prepare defensible investigational plans, coordinate pre-submission activities, and reduce delays caused by incomplete evidence, unclear study pathways, or avoidable FDA questions during the IDE process.
Our FDA 21 CFR Part 812 Services
Focused regulatory support for IDE planning, documentation, readiness, and FDA interaction management.
Pre-Sub Support
Prepare for productive FDA interactions with pathway analysis, mock meetings, strategic question development, and documentation planning that strengthens your IDE approach before formal submission.
Readiness Assessment
Evaluate whether your device, evidence package, risk files, and quality documentation are truly ready for IDE review, with prioritized remediation guidance to reduce avoidable deficiencies.
Agency Responses
Address FDA questions, requests, and action items with structured response support that improves clarity, traceability, and regulatory defensibility throughout the IDE review cycle.
Our IDE Support Process
Assess Device and Study Scope
We review your device, intended investigation, risk profile, and available evidence to determine how FDA 21 CFR Part 812 applies and what documentation will be needed for a credible IDE pathway.
Build Regulatory Strategy
Our consultants define the submission approach, identify key FDA expectations, align study objectives with regulatory requirements, and flag gaps in clinical, technical, or quality documentation before they slow review.
Prepare IDE Documentation
We support investigational plan development, risk management alignment, supporting technical summaries, and submission package organization so your IDE materials are complete, consistent, and review-ready.
Support FDA Interactions
From pre-submission preparation to deficiency responses, we help your team present clear answers, defend study rationale, and maintain momentum through FDA questions and follow-up requests.
Strengthen Ongoing Compliance
After submission, we help address updates, change impacts, and related quality system considerations so your investigation remains aligned with regulatory expectations throughout the study lifecycle.
Trusted By Manufacturers
Success Stories
Supporting device teams with structured regulatory strategy, documentation, and submission readiness.
“Excellent communication, diligent work. There is a strong quality background and QMS norms expertise.”
Samip Shah
“Professional and easy to work with! They have been instrumental in getting CE Marking for our products in the quickest way. They created clinical evaluations and risk assessment reports and provided advice on testing and manufacturing.”
Daniel Kinsey
“Highly recommend Elexes! They always meet commitments and follow through on action items.”
Joshua Mink
“Prompt and competent! Elexes should be your next regulatory consultant. Their timeline-based project plan expedited the process.”
Diane Bryant
“Excellent communication, diligent work. There is a strong quality background and QMS norms expertise.”
Samip Shah
“Professional and easy to work with! They have been instrumental in getting CE Marking for our products in the quickest way. They created clinical evaluations and risk assessment reports and provided advice on testing and manufacturing.”
Daniel Kinsey
“Highly recommend Elexes! They always meet commitments and follow through on action items.”
Joshua Mink
“Prompt and competent! Elexes should be your next regulatory consultant. Their timeline-based project plan expedited the process.”
Diane Bryant
“Excellent communication, diligent work. There is a strong quality background and QMS norms expertise.”
Samip Shah
“Professional and easy to work with! They have been instrumental in getting CE Marking for our products in the quickest way. They created clinical evaluations and risk assessment reports and provided advice on testing and manufacturing.”
Daniel Kinsey
“Highly recommend Elexes! They always meet commitments and follow through on action items.”
Joshua Mink
“Prompt and competent! Elexes should be your next regulatory consultant. Their timeline-based project plan expedited the process.”
Diane Bryant
The Elexes Difference
Why Choose Elexes?
Elexes combines regulatory depth with practical execution support for complex device pathways.
Deep Expertise
50+ years of collective experience across FDA, ISO, clinical, and quality requirements.
End-to-End Support
Guidance from development planning through submissions, approvals, and post-market obligations.
Proven Delivery
250+ successful projects across 200+ product types with strong audit outcomes.
Flexible Engagement
Project-based, part-time, or embedded support without adding permanent headcount.
Meet The Elexes Team
Experienced regulatory specialists supporting complex device programs.
Elexes Medical Consulting Pvt. Ltd. has built its reputation by helping medical device companies navigate demanding regulatory pathways with clarity and discipline. The team supports manufacturers across the full product lifecycle, from early regulatory planning and clinical documentation through submissions, approvals, and post-market obligations. With 50+ years of collective experience, Elexes brings cross-functional expertise spanning FDA, global market access, quality systems, and technical documentation. The company has completed 250+ successful projects across 200+ product types and supports clients ranging from startups to established global manufacturers. Its approach centers on reducing avoidable regulatory risk, improving submission readiness, and giving clients practical, defensible guidance that stands up to authority scrutiny.
250+ ProjectsSuccessful regulatory and compliance engagements delivered.200+ Product TypesExperience across diverse device categories and technologies.90% Audits ClearedStrong inspection and audit readiness outcomes.
Frequently Asked Questions
What is an IDE for the FDA?
An IDE, or Investigational Device Exemption, allows a medical device to be used in a clinical study to collect safety and effectiveness data before marketing authorization. Under FDA 21 CFR Part 812, an IDE may be required when a significant risk device is being studied in humans. It governs investigational plans, monitoring, records, labeling, and sponsor responsibilities.
What are the 4 categories of medical devices?
In FDA practice, devices are commonly discussed by risk-based classification and investigational status. Commercially, devices fall into Class I, Class II, or Class III based on regulatory controls and risk. In the IDE context, studies also distinguish between significant risk and non-significant risk devices. These categories affect whether an IDE submission, IRB approval, or additional FDA review is required.
When is an IDE required for a medical device study?
An IDE is generally required when a significant risk medical device will be used in a clinical investigation to collect data for FDA review. Non-significant risk studies may proceed with IRB approval alone if they meet applicable requirements. Determining the correct status depends on intended use, study design, invasiveness, and the potential risk posed to subjects.
What is the difference between significant risk and non-significant risk devices?
A significant risk device study involves implants, devices supporting or sustaining human life, devices of substantial importance in diagnosing or treating disease, or devices that otherwise present serious risk to subjects. Non-significant risk studies involve lower-risk investigations. This distinction matters because significant risk studies typically require FDA-approved IDEs, while non-significant risk studies usually follow abbreviated IDE requirements with IRB oversight.
What documents are typically included in an IDE submission?
An IDE submission commonly includes the investigational plan, prior investigations, manufacturing information, risk analysis, monitoring procedures, informed consent materials, investigator agreements, labeling, and IRB information. FDA also expects clear device descriptions and supporting technical evidence. Well-organized submissions show consistency across clinical, engineering, and quality records, which helps reduce review delays and follow-up questions.
How long does FDA IDE review usually take?
FDA generally reviews an original IDE submission within 30 days, although the practical timeline can extend if the agency requests clarifications, conditions of approval, or additional information. Preparation time before submission is often the larger variable. Strong readiness assessments, complete documentation, and clear study rationale can significantly reduce avoidable delays during the review cycle.
Can Elexes help with FDA pre-submission meetings for IDE strategy?
Yes. Elexes supports pre-submission planning by helping define the regulatory pathway, prepare briefing materials, structure key FDA questions, and conduct mock meetings. This is especially valuable when sponsors need feedback on study design, testing expectations, risk classification, or evidence strategy before filing an IDE. Early alignment can prevent costly rework later in the process.
How can a readiness assessment improve IDE submission success?
A readiness assessment identifies weaknesses before FDA does. It reviews technical documentation, risk management, clinical support, quality system alignment, and submission consistency against the expected IDE standard. The result is a prioritized action plan that helps sponsors close evidence gaps, improve traceability, and submit with greater confidence. This often reduces deficiency letters and shortens the path to study initiation.
Still Have IDE Questions?
Speak with regulatory experts about your study pathway.
Certified & Trusted
Awards and Recognition
ISO 13485
Medical device quality systems expertise.
MDSAP
Multi-market audit readiness support.
IEC 62304
Software lifecycle compliance capability.
